Intrathecal baclofen (ITB) therapy was approved for health insurance coverage in 2005 for the treatment of patients whose spasticity could not be adequately controlled by conventional therapy, and is currently being used to treat around 300 patients nationwide in Japan. Various reports have examined the efficacy and safety of ITB therapy, but no report has evaluated the patient quality of life and medical costs in Japan. A cost-utility analysis of ITB was conducted by time period in six severely spastic patients admitted to our university hospital between 2005 and 2010 for ITB therapy. The average cost of ITB therapy per quality-adjusted life year (QALY; number of years survival in perfect health) 5 years after surgery was 1,554,428 yen, below the 6 million yen willingness-to-pay threshold for 1 QALY. This study shows that ITB therapy in Japan is an outstanding treatment in medicoeconomic terms.
Introduction
Spasticity is a condition in which inhibition by the upper central nervous system is diminished due to damage to the central nervous system or conduction pathways, and reactions in the spinal cord are enhanced. Spasticity is characterized by increased muscle tension together with motor impairment or involuntary movement due to spasm or clonus. Since spastic patients have difficulty moving due to rigor in various muscles, particularly in the lower limbs, they have difficulty in performing the actions involved in activities of daily living (ADL), and their quality of life (QOL) is significantly reduced by pain and feelings of constriction. The condition is chronic and imposes major physical and psychological burdens on caregivers, meaning also significant economic losses to society. Treatment for spasticity must be evaluated from the dual perspectives of QOL and medical costs. Conventionally, oral muscle relaxant therapy has formed the main treatment for spasticity, but is not only insufficiently effective in severe cases, but increasing the dose of oral drugs also results in side effects, markedly reducing patients' QOL.
In Japan, intrathecal baclofen (ITB) therapy was approved for health insurance coverage in 2005 as a treatment for patients with spasticity not adequately controlled by conventional therapy. ITB is currently being used to treat around 300 patients nationwide, 13) contributing to the alleviation of physical and psychological suffering in patients with severe spasticity. However, further assessment of the therapeutic efficacy of ITB is needed in two classes of spastic patients: patients with impaired consciousness or communication disorder who are mainly confined to bed in hospital or long-term care facilities; and patients who are lucid but unable to stand up at home and whose social activities are largely restricted due to spasticity. ITB therapy in the first group alleviates patient spasticity, thus facilitating postural changes and excretion assistance by nurses and caregivers, so reducing caregiver burden, as well as preventing bedsores and infection. However, due to patients' impaired consciousness, there are no clear improvements in ADL, and changes in medical costs pre-and post-ITB therapy are negligible. Since evaluation of subjective QOL is difficult in these patients, conventional methods such as assessment of physical findings and ADL are primarily used to investigate ITB therapeutic efficacy. Conversely, ITB therapy in the second group delivers clear improvement in subjective QOL, such as enabling independent home living and social reintegration, ultimately reducing caregiver burden and medical costs. Despite the need to evaluate ITB therapy in this second patient group from the fresh perspectives of QOL and medical costs, no such stu- 1  spinal tumor  49  female  12  64  2  h e a di n j u r y  3 0  m a l e  1 4  2 5  3 h e a di n j u r y 4 0 m a l e 1 5 2 2 4 c e r e b r a ls t r o k e 5 9 m a l e 1 3 1 9  5  spinal injury  22  male  14  13  6  spinal tumor  49  male  15  13 *Onset-up to intrathecal baclofen therapy. **Intrathecal baclofen therapy-up to March, 2011. Cost-Effectiveness Analysis of ITB Therapy dies have been conducted in Japan to date. Analysis from these perspectives is a focal issue for the Japanese medical system, which is facing soaring medical costs due to an aging society and medical technological advancement.
In the present study, ITB therapeutic efficacy for lucid patients with severe spasticity receiving home care was assessed, with particular regard to costutility and QOL improvement.
Clinical Materials and Methods
Eight severely spastic patients were admitted to our university hospital between 2005 and 2010 for ITB therapy. Two patients were excluded from this study, one patient with adrenoleukodystrophy and one patient with cerebral infarction, because they were not lucid and so could not evaluate QOL by themselves. The subjects were six patients, five men and one woman, with a mean age of 41.5 years (Table 1) . Two patients had a confirmed diagnosis of spinal cord tumor, one of cerebral stroke, one of spinal cord damage, and two of head trauma. This study was performed as a prospective cohort study with a predetermined specified follow-up period. Subjects underwent a primary survey 1 year after surgery. In the future, a secondary survey will be performed 5 years after surgery and a tertiary survey 10 years after surgery. Only the results of the primary survey are reported here.
The degree of spasticity was evaluated before and 1 year after surgery using the Ashworth score (average score at eight sites in the lower limbs) ( Table 2 ). ADL were evaluated 1 year after onset. ADL were scored at 6 levels using the modified Rankin scale: ADL0, no symptoms; ADL1, minor symptoms which do not interfere with lifestyle; ADL2, minor handicap which leads to some restriction in lifestyle but does not interfere with the patients' capacity to look after themselves; ADL3, moderate handicap which significantly restricts lifestyle and prevents a totally independent existence; ADL4, moderately severe handicap which clearly prevents an independent existence though not needing constant attention; ADL5, severe handicap requiring constant attention night and day; and ADL6, death.
Severely spastic patients frequently experience long-term physical and psychological stress, meaning that it is important to evaluate their QOL. A variety of methods for measuring QOL are available. In this study, the utility score, which is a widely used medicoeconomic evaluation method for health-related QOL, was used. Utility is scored according to an interval scale that ranges from 0 at death to 1 in a state of perfect health. In this study, QOL was evaluated before and 1 year after surgery according to the EQ-5D Japanese version using information obtained from the patients themselves. 8) The medical costs were divided into the direct cost (DC) and indirect cost (IC). The DC included costs for medication, laboratory examinations, hospital and nursing home stay, and rehabilitation. Costs of the prescreening evaluation, test dose procedure, implantation procedure, and follow-up procedure were included in the DC. The amount was based on the charges made by the hospitals and clinics for each patient and adjusted to the cost in April 2009. Extra fees for amenities, e.g., private room fees, were excluded in this study. Costs were discounted at an annual rate of 5%, which had been recommended by the Public Health Service as the most appropriate discount rate. The IC was calculated on the basis of the estimated production loss of the patient and their family members who were responsible for nursing at home, using the Wages Census, a fundamental statistic of wages and salary structure (2009). 9, 11) The expected mean wage of the patient was used in place of the production loss, based on the mean monthly salary. For example, according to the Wages Census, the mean annual wage for all wage earners is 4,705,700 yen, including salary and special allowances. Hence, the mean monthly wage is 392,141 yen.
The production loss of each caregiver (mostly a family member of the patient) after the patient's discharge was calculated on the basis of a conversion of the time cost to the wage in the labor market. For estimating the time needed for nursing, it was assumed that ADL1, ADL2, ADL3, ADL4, and ADL5 required the following nursing times: 3,094.9, 3,882.9, 6,715.4, 10,778.5, and 14,015.8 seconds, respectively, as given in the Report of the Survey Program for Service Supply Indices. The production loss of the caregiver was calculated using the nursing time, where the time wage (2,663 yen/hr) was calculated for all wage earners by dividing the mean annual wage (4,705,700 yen) derived from the Wages Census by the annual working time (1,767 hrs) obtained from the time occupied in regular work and overtime work.
Utility scores before and after surgery were multiplied by the number of years of activity to calculate the quality-adjusted life years (QALY) for each patient. 5, 14) The first patients to enter the study had already completed 5 years since surgery, but there had been no change in their utility scores between 1 and 5 years after surgery. The battery life for patients' pumps is 7 years, meaning that no data are yet available for patients who have had pumps re-implanted. Therefore, a cost-utility analysis was performed assuming a 5-year period after surgery. Sensitivity analyses were performed to consider the effect of changes in costs (discount rate 0-10%).
Changes in utility scores, Ashworth scores, and medical costs before and after surgery were evaluated using paired t-tests. Differences were regarded as significant if the p value was less than 0.05.
Results
Evaluation of outcome showed a significant improvement 1 year after surgery in terms of average ADL (3.83 before surgery, 2.33 after), Ashworth score (3.17 before surgery, 2.04 after), and utility score (0.242 before surgery, 0.662 after) ( Table 3) .
With ITB therapy, screening tests are first carried out to confirm the efficacy of ITB administration, and if the intervention is confirmed to be effective, a pump is implanted inside the body. After the pump has been implanted, it is refilled with the drug once every 3 months as an outpatient procedure. The average medical costs required for ITB therapy are 2,650,000 yen, which is the inpatient cost of screening and pump implantation (including the costs of surgery, anesthetic, medication, and hospital stay), and the cost of refilling the pump with the drug once every 3 months is around 49,000 yen, including the costs of both the procedure and the drug. These comprise the increased medical costs associated with ITB therapy. Conversely, ADL levels are greatly improved as a result of ITB therapy, and ICs are reduced as a result of improvements in the living environment (Table 4 ). The fact that oral drugs are no longer required to treat spasticity also contributes to decreasing DCs. In this study, DCs increased from 37,500 yen to 46,000 yen/month. ICs were calculated in terms of lost production per patient and person engaged in nursing care, and as time spent in nursing care is strongly correlated with ADL, this decreased by more than 100,000 yen per month, from 613,170 yen to 511,443 yen.
The average cost of ITB therapy per QALY 5 years after surgery was 1,554,428 yen (Table 5) . Even when the sensitivity analysis taking discount rates Values are cost per quality-adjusted life years (Japanese yen).
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Cost-Effectiveness Analysis of ITB Therapy into account was performed, the cost per QALY ranged from 1,533,035 yen to 1,582,528 yen.
Discussion
This study demonstrated that ITB therapy is an outstanding treatment in terms of both QOL and medical costs in Japan. At the same time, this study has emphasized that severely spastic patients were forced into a life of psychological and mental suffering for many years until ITB therapy became covered by insurance. Various attempts have been made to quantify QOL, and the present study used utility, which is referred to as health-related QOL. This measure restricts QOL to physical activity and mental function (activity) for evaluation, and uses an interval scale from 0 (death) to 1 (complete health). The present study evaluated the QOL of the patients at the time of evaluation using the EQ-5D Japanese version (Table 6 ). 8) The EQ-5D Japanese version assesses QOL in terms of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression. Utility is calculated from the responses to five standardized questions, one for each of the five dimensions. For each question, the best response is selected from three alternatives. Utility is calculated from the responses using the Japanese version of the utility conversion table. 8) Self-evaluations using the EQ-5D Japanese version to evaluate patient QOL have been shown to offer excellent reliability and validity. Therefore, self-evaluations by patients were used to calculate patient QOL in the present study. Before surgery, some patients recorded a utility score close to zero, due to low scores on questions concerning pain/discomfort and anxiety/ depression on the EQ-5D Japanese version. This is also an area that could not be adequately evaluated by the conventional ADL and Ashworth scores. 6, 23) The advantage of utility is that the QOL of patients with different conditions can be evaluated using a single index. Therefore, utility is extremely useful Table 6 Scoring the EQ-5D descriptive system
By placing a tick in one box in each group below, please indicate which statements best describe your own health state today. for clinical decisions such as treatment selection, economic evaluations, or policymaking.
Mobility
The medical economic analysis of cost-utility used QALY, which integrates quality and quantity of life. A QOL of utility 1 maintained for 1 year is 1 QALY, and the medical costs required to obtain 1 QALY are calculated for cost-utility analysis. The advantage of cost-utility analysis is that it crosses the divisions between different medical departments, allowing comparison of the medical economic effects of different medical interventions. Current medical services in Japan need to make effective use of limited medical resources, and so it is essential for medical policymaking to be able to evaluate different medical interventions using equivalent criteria for prioritization. In Western countries, there is generally a ceiling of $50,000/QALY, up to which medical interventions can be considered from a medical economic standpoint.
This study had several limitations. First, the number of subjects, only six patients, was small, because the study was limited to the number of patients treated at a single institution, and, in the future, it will be necessary to consider joint studies with other institutions. Another issue is that the cost-utility analysis assumed a short period of 5 years after surgery, but because of pump battery life, long-term follow up lasting 7-10 years is required. Because only 5 years have passed since ITB therapy became covered by insurance, it is not possible at this point to obtain accurate data on medical costs required for pump reimplantation (pump replacement) and utility scores. We must await the results of the secondary and tertiary surveys. However, the medical costs required by pump re-implantation are estimated as totaling something under 2 million yen, given that the technical cost of pump re-implantation is 39,000 yen, a pump costs 1,630,000 yen, and around 1 week's hospitalization is required. On the other hand, ITB therapy enables medical costs to be reduced by around 90,000 yen/month in terms of DCs and ICs, or a total of 1,000,000 yen/year, and as pump battery life is around 7 years, the total reduction in medical costs (1,000,000 yen × 7) would cover the cost of pump re-implantation.
Adverse events resulting from ITB therapy should also be considered. Fortunately, there were no adverse events during the period in our university and those impacts were not included in this study. But in the cost effectiveness analysis, medical cost must be calculated supposing the worst scenario. The incident rate of adverse events was 25.0% in a national treatment outcome study conducted in Japan in 2009. 13) The incidence of adverse drug reaction such as headache, seizure, dizziness, etc. was reported to be 12.6%. Most events occurred within 60 days after pump implantation, and were transient and resolved. Therefore, the impacts on the increase in medical costs are small. On the other hand, serious complications such as problems with the tube and pump system were reported, including tube rupture, tube displacement, and pump malfunction. The incidence of tube problems was 8.5%. These cases require re-hospitalization and repeat surgery. The medical costs required by tube exchange are estimated as totaling something under 500 thousand yen, given that the tube costs 69,100 yen, and around 1 week's hospitalization is required. The incidence of pump problems was 1.8%. Pump exchange due to pump malfunction requires about 2 million yen, given that a pump costs 1,630,000 yen, and around 1 week's hospitalization is required. These serious complications contribute to increased medical costs to some extent, but these are low incidences and have little impact on this cost utility analysis.
A number of reports from Europe and the United States have examined the cost-utility analysis of ITB therapy. 1, 2, 4, 7, 12, [17] [18] [19] [20] [21] Cost per QALY ranged from $10,550 to $19,570, well below the $50,000 willingness-to-pay for 1 QALY regarded as the guideline for evaluating the value of medical technologies. In the present study, the cost per QALY of ITB therapy in Japan was 1,554,428 yen, or $19,430 in U.S. dollars, far below the $50,000 figure. 3, 10, 22) From a medicoeconomic perspective, it would not be cor-Neurol Med Chir (Tokyo) 52, July, 2012
Cost-Effectiveness Analysis of ITB Therapy rect to compare these values directly. The many differences between factors, such as the medical policies and cost of medical materials in different countries, must be taken into account. Great differences are seen between different countries even in the reimbursement cost of pumps, which stands at 1,630,000 yen in Japan, $11,200 in the United States, £7,850 in the United Kingdom, and 10,098 in Germany. Japanese medical costs tend to be comparatively higher than those in the United States and Europe in terms of the cost of medical materials, and the results of our analysis must be judged with even greater caution with respect to how outstanding the cost-benefit really is. However, willingness-to-pay for 1 QALY in Japan has been found by other studies to be around the same level as that in Europe and the United States, and the most recent report has stated that 6 million yen is an appropriate value. 15, 16) The figure of 1,554,428 yen calculated in this study is far below that value, showing that ITB therapy has outstanding therapeutic ratio, both in Japan and overseas.
This study was the first cost-utility analysis of ITB therapy in Japan. To refine our analysis will require increasing the number of subjects and extending the follow-up period over the long term, but the results of this study demonstrated that ITB therapy has outstanding therapeutic ratio, as reported in studies from the United States and Europe.
